China SXT Pharmaceuticals (SXTC) Current Assets (2018 - 2026)

China SXT Pharmaceuticals has reported Current Assets for 9 years, with the latest figure at $34.5 million in Q1 2026.

• On a quarterly basis, Current Assets rose 62.04% year-over-year to $34.5 million in Q1 2026; TTM through Mar 2026 was $34.5 million, a 62.04% increase from a year earlier, with the FY2026 full-year figure at $34.5 million, up 62.04% from the prior year.
• Current Assets was $34.5 million for Q1 2026 at China SXT Pharmaceuticals, up from $26.0 million in the prior quarter.
• The five-year high for Current Assets was $34.5 million in Q1 2026, with the low at $12.4 million in Q3 2022.
• Average Current Assets over 5 years is $20.7 million, with a median of $21.3 million recorded in 2025.
• The largest YoY upside for Current Assets was 62.93% in 2024 against a maximum downside of 27.09% in 2024.
• Over 5 years, Current Assets stood at $12.4 million in 2022, then increased by 9.19% to $13.5 million in 2023, then soared by 62.93% to $22.0 million in 2024, then advanced by 18.44% to $26.0 million in 2025, then soared by 32.51% to $34.5 million in 2026.
• The last three Current Assets figures came in at $34.5 million (Q1 2026), $26.0 million (Q3 2025), and $21.3 million (Q1 2025), per Business Quant data.